MetaVia Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on November 5, 2026, disclosing positive interim clinical trial data and an updated corporate presentation.

Key Highlights

  • Positive interim data: MetaVia announced positive interim data from Part 3B of its Phase 1 clinical trial of DA-1726.
  • Novel compound: DA-1726 is described in the filing as a novel oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors.
  • Data disclosure method: The interim data were announced via a press release furnished as Exhibit 99.1 to the filing.
  • Corporate presentation: The company also posted an updated corporate presentation, attached as Exhibit 99.2, dated November 2026.
  • Regulation FD: The clinical data disclosure was made under Item 7.01, Regulation FD Disclosures, and is furnished, not filed, for purposes of Section 18 of the Exchange Act.
  • Signed by CEO: The report was signed by Hyung Heon Kim, President and Chief Executive Officer of MetaVia Inc.

DA-1726 Phase 1 Interim Results and MetaVia's Dual-Receptor Drug Candidate

MetaVia Inc. (NASDAQ:MTVA), a Delaware-incorporated biopharmaceutical company headquartered at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts, filed this 8-K to disclose interim clinical findings for DA-1726, its lead drug candidate. According to the filing, DA-1726 is a novel oxyntomodulin analog designed to act on two receptor targets: the GLP-1 receptor (GLP1R) and the glucagon receptor (GCGR). The compound's dual-receptor mechanism distinguishes it from single-receptor GLP-1 agents, and the filing describes the data released as coming from Part 3B of an ongoing Phase 1 clinical trial.

The company disclosed the interim data through a press release dated November 5, 2026, which is furnished as Exhibit 99.1. The filing specifies that information provided under Item 7.01, including Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934." Separately, under Item 8.01, the company disclosed that it posted an updated corporate presentation, Exhibit 99.2, which management may use in connection with investor communications or conferences. The filing notes that information accessible through any referenced website is not incorporated by reference into the report and is treated as an inactive textual reference only.

The filing includes a forward-looking statements notice, indicating that statements in the report and its exhibits "are based on current expectations and are not guarantees of future performance," and that "actual events or results may differ materially from those in the forward-looking statements." These are the company's own characterizations and are subject to its cautionary language as stated in Exhibits 99.1 and 99.2 and other regulatory filings.

What Was Disclosed

MetaVia Inc. filed an 8-K on November 5, 2026, reporting positive interim Phase 1 data for its dual GLP-1 and glucagon receptor-targeting compound DA-1726, along with an updated corporate presentation. Both disclosures were furnished, not filed, under Regulation FD and Item 8.01 respectively.